Elsevier

The Journal of Pediatrics

Volume 117, Issue 3, September 1990, Pages 364-370
The Journal of Pediatrics

Original article
Preserving adult height potential in girls with idiopathic true precocious puberty

https://doi.org/10.1016/S0022-3476(05)81074-1Get rights and content

We designed a prospective study of height potential in giris with idiopathic precocious puberty, comparing the presenting features of giris with and without evidence of reduced adult height potential. The 14 giris with impaired adult helght prognoses (group 1) were reexamined after treatment with a gonadotropin releasing hormone agonist, nafarelin. The seven giris with the prognosis of unimpaired height (group 2) were followed without therapy. We found that the group could be distinguished at initial examination by the greater bone age/height age ratio of group 1 (mean ± SEM: 1.4 ± 0.06 vs 1.0 ± 0.05; p <0.005) and by the greater difference between predicted height and target height in group 1. The mean predicted height in group 1 was significantly less than the mean target height (150.7 ± 2.1 vs 165.4 ± 3.0 cm; p<0.005), whereas the mean predicted and target heights in group 2 were similar (165.4 ± 3.0 vs 164.3 ± 2.1 cm). Initial estradiol levels were also greater in group 1 than in group 2 (21.6 vs 10.6 pg/ml; p<0.05), although this difference was not sustained during follow-up. In group 1, nafarelin therapy suppressed the pltuitary-gonadal axis, and although there was a transient reduction in height potential in giris with the youngest bone ages during the first 6 months of therapy, 2 years of treatment slightly improved predicted heights from 150.7 ± 2.1 to 152.7 ± 2.0 cm (p<0.05). Height predictions also increased without therapy during the 2-year observation period in group 2, from 165.4 ± 3.0 to 168.7 ± 4.1 cm (p<0.05). Our data indicate that gonadotropin releasing hormone agonist therapy preserves height potential in giris with an initially impaired height prognosis, and that height potential is preserved without therapy in those with a good initial height prognosis.

References (38)

  • ThamdrupE

    Precocious sexual development

    (1961)
  • SigurjonsdottirTJ et al.

    Precocious puberty: a report of 96 cases

    Am J Dis Child

    (1968)
  • MussamD et al.

    Precocious puberty: a follow-up study

    Arch Dis Child

    (1984)
  • KuppermanHS et al.

    Medroxyprogesterone acetate in the treatment of constitutional sexual precocity

    J Clin Endocrinol Metab

    (1962)
  • LeePA

    Medroxyprogesterone therapy for sexual precocity in girls

    Am J Dis Child

    (1981)
  • KauliR et al.

    Cyproterone acetate in treatment of precocious puberty

    Arch Dis Child

    (1976)
  • SorgoW et al.

    The effects of cyproterone acetate on statural growth in children with precicious puberty

    Acta Endocrinol (Copenh)

    (1987)
  • ComiteF et al.

    Short-term treatment of idiopathic precocious puberty with a long-acting analogue of luteinizing hormonereleasing hormone: a preliminary report

    N Engl J Med

    (1981)
  • ComiteF et al.

    Luteinizing hormone releasing hormone analogue therapy for central precocious puberty: long-term effect on somatic growth, bone maturation, and predicted height

    JAMA

    (1986)
  • Cited by (85)

    • Precocious Puberty

      2015, Endocrinology: Adult and Pediatric
    • Puberty: Ontogeny, Neuroendocrinology, Physiology, and Disorders

      2011, Williams Textbook of Endocrinology, Twelfth Edition
    • Precocious Puberty

      2010, Endocrinology: Adult and Pediatric, Sixth Edition
    • Current Concepts in Normal and Abnormal Puberty

      2007, Current Problems in Pediatric and Adolescent Health Care
      Citation Excerpt :

      In some children with CPP, puberty may progress at a slow rate, and treatment may not be necessary. Untreated girls with CPP that is not progressive or rapidly progressive do not have a compromised final adult height.50,51 Therefore, in children who are diagnosed early with idiopathic CPP, a period of at least 6 months is a reasonable amount of time to observe growth and the tempo of pubertal progression.

    View all citing articles on Scopus

    Supported in part by U.S. Public Health Service grants RR-00055 (General Clinical Research Center), NIADDK 07011-15 (M.K.), and HD-06308 (R.L.R.) and in part by Syntex Corporation.

    View full text